Crinetics (CRNX) Is Up 6.1% After New Paltusotine Data Presented at Neuroendocrine Tumor Meeting

• Crinetics Pharmaceuticals announced that three abstracts from its clinical development programs, including preliminary Phase 2 data on paltusotine in neuroendocrine tumor patients, were presented at the North American Neuroendocrine Tumor Society Annual Meeting on October 23-25, 2025.
• The company highlighted encouraging results, with paltusotine showing a 74% progression-free survival rate and improvements in key symptoms for carcinoid syndrome patients, underscoring its potential beyond current FDA-approved uses.
• With this additional clinical data in focus, we examine how expansion into new indications could impact Crinetics Pharmaceuticals' investment narrative.

Explore 28 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

What Is Crinetics Pharmaceuticals' Investment Narrative?

For investors considering Crinetics Pharmaceuticals, the big picture is all about belief in the company’s ability to expand its lead drug, paltusotine, into new markets and indications. The recent presentation of Phase 2 data showing a 74% progression-free survival rate for carcinoid syndrome patients highlights a meaningful step forward, potentially strengthening the case for paltusotine’s commercial reach beyond its current FDA-approved use in acromegaly. While CRNX remains unprofitable and is facing growing losses, encouraging clinical trial results like these can act as short-term catalysts, particularly ahead of pivotal Phase 3 readouts. Still, the most significant risks remain tied to future approvals and successful commercialization. If this momentum carries into regulatory success or transforms into meaningful revenue, the catalysts could shift materially, offering new reasons for optimism. Otherwise, the long-standing revenue gap persists as a material concern.

But, pressure from mounting losses and a limited sales base shouldn’t be overlooked. Crinetics Pharmaceuticals' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Three Simply Wall St Community estimates peg Crinetics’ fair value from as low as US$8.51 to over US$1,000, with the majority falling between US$8.51 and US$116. This spread reflects sharply different views on the commercial risk and clinical milestones ahead, echoing the uncertainty that shapes near-term catalysts for the stock. You’ll find investors see things from every angle.

Explore 3 other fair value estimates on Crinetics Pharmaceuticals - why the stock might be worth less than half the current price!

Build Your Own Crinetics Pharmaceuticals Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Crinetics Pharmaceuticals research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Crinetics Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Crinetics Pharmaceuticals' overall financial health at a glance.

No Opportunity In Crinetics Pharmaceuticals?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• We've found 22 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• These 15 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com